Last 12 months
Inside the activity.
0 purchase rows · 36 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 17 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2021 Filed Jun 7, 2021 20:40 UTC |
Machado PatrickDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038628 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:42 UTC |
PERLMAN ANDREW JDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038635 · doc4.xml · derivative · entry 2 PERLMAN ANDREW J · CIK 0001201617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:42 UTC |
PERLMAN ANDREW JDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038635 · doc4.xml · nonDerivative · entry 1 PERLMAN ANDREW J · CIK 0001201617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,525 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:38 UTC |
Lacey David L.Director
|
GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038623 · doc4.xml · derivative · entry 2 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:38 UTC |
Lacey David L.Director
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038623 · doc4.xml · nonDerivative · entry 1 Lacey David L. · CIK 0001734422 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,352 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:36 UTC |
KANEKO YASUNORIDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038619 · doc4.xml · derivative · entry 5 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F4 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:36 UTC |
KANEKO YASUNORIDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038619 · doc4.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021. F3 · balance_after: Four thousand one hundred thirty-three (4,133) shares previously held directly by the reporting person were transferred to reporting person's trust. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:34 UTC |
FALBERG KATHRYN EDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,100 | $0.00 Strike: $24.79 | $0.00 |
DisclosureSEC source: 0001209191-21-038616 · doc4.xml · derivative · entry 3 FALBERG KATHRYN E · CIK 0001206977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,100 Underlying: Common Stock · 14,100 shares Expires 2031-06-02 F3 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 20:34 UTC |
FALBERG KATHRYN EDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-038616 · doc4.xml · nonDerivative · entry 1 FALBERG KATHRYN E · CIK 0001206977 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,504 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 3, 2022 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control. F2 · balance_after: Includes 3,000 shares of restricted stock units (previously reported) that vested on June 3, 2021. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:16 UTC |
KANEKO YASUNORIDirector
|
PurchaseCommon Stock | 4,133 | $31.37 | $129,652.21 |
DisclosureSEC source: 0001179110-21-004605 · edgar.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,133 F1 · shares: Shares purchased in a private transaction from Dr. William Grossman, Arcus's Chief Medical Officer. F2 · balance_after: Thirty-five thousand (35,000) shares previously held directly by the reporting person were transferred to reporting person's trust. F3 · balance_after: The reporting person's direct ownership includes three thousand (3,000) shares that are Restricted Stock Units that will not vest until June 3, 2021. Read SEC document |
| April 23, 2021 Filed Apr 26, 2021 20:14 UTC |
Grossman WilliamChief Medical Officer
|
SaleCommon Stock | 4,133 | $31.37 | $129,652.21 |
DisclosureSEC source: 0001179110-21-004603 · edgar.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,717 F1 · shares: Shares sold in a private transaction to Dr. Yasunori Kaneko, a director of Arcus Biosciences, Inc. The shares, representing approximately 1.6% of the total shares either owned or that may be acquired by Dr. Grossman upon exercise of options that are vested and exercisable, were sold by Dr. Grossman as part of his tax plan. Read SEC document |
| March 31, 2021 Filed Apr 2, 2021 15:38 UTC |
FALBERG KATHRYN EDirector
|
PurchaseCommon Stock | 20,000 | $28.35 | $566,996.00 |
DisclosureSEC source: 0001209191-21-024405 · doc4.xml · nonDerivative · entry 1 FALBERG KATHRYN E · CIK 0001206977 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 102,106 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $27.96 to $28.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:37 UTC |
Grossman WilliamChief Medical Officer
|
SaleCommon Stock | 2,127 | $35.03 | $74,508.60 |
DisclosureSEC source: 0001209191-21-021772 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,850 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.98 to $35.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 20:36 UTC |
Jarrett JenniferDirector · Chief Operating Officer
|
SaleCommon Stock | 8,661 | $35.03 | $303,393.96 |
DisclosureSEC source: 0001209191-21-021770 · doc4.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,973 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. F2 · price: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $34.98 to $35.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 22:02 UTC |
ROSEN TERRY JDirector · Chief Executive Officer
|
GiftCommon Stock | 311,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-007780 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Rosen GRAT No. 1 Disclosed balance after: 0 F1 · balance_after: 311,900 shares were transferred to various family trusts in which the reporting person has no pecuniary interest, but retains voting and dispositive power over all of the shares transferred to each trust. The remaining 86,450 shares were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 21:52 UTC |
GILEAD SCIENCES, INC.10% owner
|
PurchaseCommon Stock | 5,650,000 | $39.00 | $220,350,000.00 |
DisclosureSEC source: 0001104659-21-010972 · a4.xml · nonDerivative · entry 1 GILEAD SCIENCES INC · CIK 0000882095 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,913,029 Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 16:16 UTC |
Tang Carolyn C.General Counsel
|
GrantStock Option (right to buy) · Derivative | 75,225 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004280 · doc4.xml · derivative · entry 2 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,225 Underlying: Common Stock · 75,225 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 16:16 UTC |
Tang Carolyn C.General Counsel
|
GrantCommon Stock | 12,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004280 · doc4.xml · nonDerivative · entry 1 Tang Carolyn C. · CIK 0001836662 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,886 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:14 UTC |
ROSEN TERRY JDirector · Chief Executive Officer
|
GrantStock Option (right to buy) · Derivative | 280,000 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004277 · doc4.xml · derivative · entry 5 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,000 Underlying: Common Stock · 280,000 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:14 UTC |
ROSEN TERRY JDirector · Chief Executive Officer
|
GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004277 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,393 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:13 UTC |
Jarrett JenniferDirector · Chief Operating Officer
|
GrantCommon Stock | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004275 · doc4.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,634 F1 · shares: Represents the grant of restricted stock units that vest in quarterly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:12 UTC |
Jaen Juan C.Director · President
|
GrantStock Option (right to buy) · Derivative | 116,250 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004270 · doc4.xml · derivative · entry 3 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,250 Underlying: Common Stock · 116,250 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:12 UTC |
Jaen Juan C.Director · President
|
GrantCommon Stock | 19,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004270 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 208,768 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:11 UTC |
Grossman WilliamChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 112,500 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004265 · doc4.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:11 UTC |
Grossman WilliamChief Medical Officer
|
GrantCommon Stock | 18,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004265 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,477 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:10 UTC |
Goeltz II Robert C.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $36.73 | $0.00 |
DisclosureSEC source: 0001209191-21-004260 · doc4.xml · derivative · entry 2 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-01-18 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| January 19, 2021 Filed Jan 20, 2021 21:10 UTC |
Goeltz II Robert C.Chief Financial Officer
|
GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-004260 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after January 1, 2021, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 00:58 UTC |
PERLMAN ANDREW JDirector
|
GrantStock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $31.77 | $0.00 |
DisclosureSEC source: 0001209191-20-064561 · doc4.xml · derivative · entry 3 PERLMAN ANDREW J · CIK 0001201617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2030-12-16 F2 · derivative.exercise_date: The option is exercisable in 36 equal monthly installments after December 17, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 17, 2020 Filed Dec 19, 2020 00:58 UTC |
PERLMAN ANDREW JDirector
|
GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-064561 · doc4.xml · nonDerivative · entry 2 PERLMAN ANDREW J · CIK 0001201617 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,500 F1 · shares: Represents the grant of restricted stock units that vest in three equal annual installments on each of December 15, 2021, December 15, 2022 and December 15, 2023, subject to the Reporting Person's continued service to the Company. Read SEC document |
| December 16, 2020 Filed Dec 18, 2020 21:51 UTC |
Grossman WilliamChief Medical Officer
|
SaleCommon Stock | 2,117 | $31.35 | $66,367.95 |
DisclosureSEC source: 0001209191-20-064444 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,727 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of certain RSUs, previously reported in Table I following the date of grant. F2 · balance_after: Includes 992 shares purchased on 5/29/2020 and 1,002 shares purchased on 11/30/2020 through the Company's Employee Stock Purchase Plan. Read SEC document |
| October 13, 2020 Filed Oct 15, 2020 20:46 UTC |
Jaen Juan C.Director · President
|
GiftCommon Stock | 1,207,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-054918 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 1,572,240 F1 · price: Gift to various family trusts over which the reporting person has neither voting nor investment control. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 21:02 UTC |
Grossman WilliamChief Medical Officer
|
GrantStock Option (right to buy) · Derivative | 100,000 | $17.00 Strike: $17.00 | $1,700,000.00 |
DisclosureSEC source: 0001209191-20-053710 · doc4.xml · derivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2030-10-01 F2 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after October 2, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| October 02, 2020 Filed Oct 5, 2020 21:02 UTC |
Grossman WilliamChief Medical Officer
|
GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053710 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,600 F1 · shares: Represents the grant of restricted stock units that vest in quarterly installments after October 2, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:01 UTC |
Jarrett JenniferDirector · Chief Operating Officer
|
GrantStock Option (Right to Buy) · Derivative | 900,000 | $0.00 Strike: $17.17 | $0.00 |
DisclosureSEC source: 0001209191-20-053707 · doc4.xml · derivative · entry 2 Jarrett Jennifer · CIK 0001671311 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 900,000 Underlying: Common Stock · 900,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after October 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| September 09, 2020 Filed Sep 9, 2020 20:53 UTC |
Goeltz II Robert C.Chief Financial Officer
|
PurchaseCommon Stock | 5,000 | $21.57 | $107,848.50 |
DisclosureSEC source: 0001209191-20-049846 · doc4.xml · nonDerivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.10 to $22.06, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| August 10, 2020 Filed Aug 11, 2020 21:13 UTC |
ROSEN TERRY JDirector · Chief Executive Officer
|
PurchaseCommon Stock | 32,050 | $23.38 | $749,402.72 |
DisclosureSEC source: 0001209191-20-046182 · doc4.xml · nonDerivative · entry 2 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rosen Family Trust Disclosed balance after: 3,231,179 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $22.69 to $23.60, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: 101,650 and 62,685 shares previously held by the reporting person in Rosen GRAT No. 1 and No. 2, respectively, were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. Read SEC document |
| August 07, 2020 Filed Aug 11, 2020 21:13 UTC |
ROSEN TERRY JDirector · Chief Executive Officer
|
PurchaseCommon Stock | 11,655 | $21.44 | $249,911.17 |
DisclosureSEC source: 0001209191-20-046182 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · By The Rosen Family Trust Disclosed balance after: 3,199,129 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $21.11 to $21.50, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · balance_after: 101,650 and 62,685 shares previously held by the reporting person in Rosen GRAT No. 1 and No. 2, respectively, were transferred into the Rosen Family Trust in a transaction exempt from Section 16 reporting pursuant to Rule 16a13. Read SEC document |
| August 03, 2020 Filed Aug 4, 2020 22:53 UTC |
Goeltz II Robert C.Chief Financial Officer
|
GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $21.06 | $0.00 |
DisclosureSEC source: 0001209191-20-044848 · doc4.xml · derivative · entry 1 Goeltz II Robert C. · CIK 0001653881 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-07-31 F1 · derivative.exercise_date: The option is exercisable in 48 equal monthly installments after August 1, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 22:13 UTC |
Grossman WilliamChief Medical Officer
|
PurchaseCommon Stock | 100 | $19.68 | $1,967.56 |
DisclosureSEC source: 0001209191-20-044798 · doc4.xml · nonDerivative · entry 2 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 Read SEC document |
| July 31, 2020 Filed Aug 4, 2020 22:13 UTC |
Grossman WilliamChief Medical Officer
|
PurchaseCommon Stock | 100 | $19.77 | $1,977.00 |
DisclosureSEC source: 0001209191-20-044798 · doc4.xml · nonDerivative · entry 1 Grossman William · CIK 0001730229 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:31 UTC |
KANEKO YASUNORIDirector
|
Exercise / conversionStock Option (Rights to Buy) · Derivative | 35,000 | $0.00 Strike: $7.99 | $0.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · derivative · entry 7 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2020 Filed Jun 8, 2020 20:31 UTC |
KANEKO YASUNORIDirector
|
Exercise / conversionCommon Stock | 35,000 | $7.99 | $279,650.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · nonDerivative · entry 2 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the exercise of options to purchase common stock by the reporting person. No shares were sold by the reporting person, and the shares received upon the exercise of such options are subject to a lock-up agreement with the underwriters for the Company's recent public offering. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:35 UTC |
ROSEN TERRY JDirector · Chief Executive Officer
|
GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034995 · doc4.xml · nonDerivative · entry 1 ROSEN TERRY J · CIK 0001182473 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,393 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after June 4, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:34 UTC |
Ribas AntoniDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $30.05 | $0.00 |
DisclosureSEC source: 0001209191-20-034991 · doc4.xml · derivative · entry 3 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:34 UTC |
Ribas AntoniDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034991 · doc4.xml · nonDerivative · entry 1 Ribas Antoni · CIK 0001792164 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,050 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:32 UTC |
Machado PatrickDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $30.05 | $0.00 |
DisclosureSEC source: 0001209191-20-034986 · doc4.xml · derivative · entry 2 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F2 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:32 UTC |
Machado PatrickDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034986 · doc4.xml · nonDerivative · entry 1 Machado Patrick · CIK 0001311210 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:27 UTC |
Jaen Juan C.Director · President
|
GrantCommon Stock | 55,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034981 · doc4.xml · nonDerivative · entry 1 Jaen Juan C. · CIK 0001422996 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,393 F1 · shares: Represents the grant of restricted stock units that vest in four equal annual installments after June 4, 2020, subject to the Reporting Person's continued service to the Company. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:31 UTC |
KANEKO YASUNORIDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,000 | $0.00 Strike: $30.05 | $0.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · derivative · entry 6 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Underlying: Common Stock · 14,000 shares Expires 2030-06-03 F3 · derivative.exercise_date: The option will vest in full on the earlier of (i) 12 months following the date of grant or (ii) the date of the next annual stockholder meeting following the grant. The option becomes fully vested and exercisable in the event the Company is subject to a change in control. Read SEC document |
| June 04, 2020 Filed Jun 8, 2020 20:31 UTC |
KANEKO YASUNORIDirector
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-034985 · doc4.xml · nonDerivative · entry 1 KANEKO YASUNORI · CIK 0001277503 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 F1 · shares: Represents the grant of restricted stock units that vest 100% on the earlier of June 4, 2021 or the next annual meeting of the stockholders of the issuer. The RSUs will become fully vested in the event the Company is subject to a change in control Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.